News & Updates

Show Multimedia Only

Real-world study: FF/UMEC/VI step-up therapy for COPD comparatively more advantageous than BUD/GLY/FORM

16 Sep 2025

Stepping up to triple therapy with inhaled corticosteroid (ICS) plus a long-acting muscarinic antagonist (LAMA) and a long-acting β2-agonist (LABA) is recommended for patients with chronic obstructive pulmonary disease (COPD) inadequately controlled with dual therapy. The use of single-inhaler therapy has also been recommended over the use of multiple inhalers, as convenience has been associated with better treatment adherence and effectiveness. This article highlights the results of the first real-world comparative effectiveness study of two single-inhaler triple therapy (SITT) formulations, fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) and budesonide/ glycopyrrolate/formoterol fumarate (BUD/GLY/FORM), in patients who stepped up from prior dual combination therapy.

Real-world study: FF/UMEC/VI step-up therapy for COPD comparatively more advantageous than BUD/GLY/FORM

16 Sep 2025

IL-23 inhibitor use in a PsA patient with inadequate response to prior bDMARDs

10 Jul 2025 by

A 29-year-old lady with heavily pretreated psoriatic arthritis (PsA) was referred to our clinic in 2021.

IL-23 inhibitor use in a PsA patient with inadequate response to prior bDMARDs

10 Jul 2025

$Achieving remission with anti–IL-5 therapy in a patient with adult-onset asthma and refractory EGPA$

Achieving remission with anti–IL-5 therapy in a patient with adult-onset asthma and refractory EGPA

24 May 2025 by

A 57-year-old lady presented in January 2015 with bilateral lower limb numbness, vasculitic rash over her lower limb, shortness of breath, and sudden loss of vision in her left eye. She had a history of adult-onset asthma for more than 10 years (managed with inhaled corticosteroids and bronchodilator), and had two episodes of exacerbation 6 months before presentation. Other comorbidities included allergic rhinitis and paroxysmal atrial fibrillation.

Achieving remission with anti–IL-5 therapy in a patient with adult-onset asthma and refractory EGPA

24 May 2025

Anti–IFN-α receptor mAb treatment for an SLE patient previously treated with rituximab and belimumab

22 Apr 2025 by

A 24-year-old clerk and mother of two presented to our hospital in August 2010 with fever, malar rash on the face, vasculitic rash on the fingers and alopecia. Her medical and family histories were unremarkable.

Anti–IFN-α receptor mAb treatment for an SLE patient previously treated with rituximab and belimumab

22 Apr 2025

News & Updates

Showing Rheumatology articles

Showing

Specialty:

Real-world study: FF/UMEC/VI step-up therapy for COPD comparatively more advantageous than BUD/GLY/FORM

Real-world study: FF/UMEC/VI step-up therapy for COPD comparatively more advantageous than BUD/GLY/FORM

IL-23 inhibitor use in a PsA patient with inadequate response to prior bDMARDs

IL-23 inhibitor use in a PsA patient with inadequate response to prior bDMARDs

Achieving remission with anti–IL-5 therapy in a patient with adult-onset asthma and refractory EGPA

Achieving remission with anti–IL-5 therapy in a patient with adult-onset asthma and refractory EGPA

Anti–IFN-α receptor mAb treatment for an SLE patient previously treated with rituximab and belimumab

Anti–IFN-α receptor mAb treatment for an SLE patient previously treated with rituximab and belimumab